econintersect.com
       
  

FREE NEWSLETTER: Econintersect sends a nightly newsletter highlighting news events of the day, and providing a summary of new articles posted on the website. Econintersect will not sell or pass your email address to others per our privacy policy. You can cancel this subscription at any time by selecting the unsubscribing link in the footer of each email.



posted on 16 February 2017

This Chart Reveals A Hidden Bull Market

by Greg Guenthner, Daily Reckoning

There's nothing quite like an earnings-driven comeback. Especially when you're dealing with a speculative sector that's taken a beating recently.

That's exactly what we're seeing from biotech stocks right now.

The biggest names in the industry are starting to impress investors once again. In fact, a handful of high-profile earnings beats are one of the reasons we're seeing resurging prices throughout the sector.

The positive biotech headlines just keep coming this month...

Biotech mainstay Amgen Inc. (NASDAQ:AMGN) reported that its anti-cholesterol drug successfully reduced heart attacks and beat earnings estimates. Amgen shares are up nearly 7% this month alone - and they're up an impressive 27% since the election.

Celgene Corp. (NASDAQ:CELG) is another big biotech that has slowly consolidated its post-election gains. Now its price also beginning to perk up. The company's flagship blood-cancer drug continues to churn out double-digit sales growth, MarketWatch notes.

Then there's Biogen Inc. (NASDAQ:BIIB). The company beat earnings - but gave squishy guidance for the year. Even so, shares are beginning to firm. Biogen stock hasn't posted a down day since Jan. 30th.

Add 'em all up and you get a brand new biotech bull.


What is the Income Play Rich Investors Love? (Hint: It's Tax-Free)


The major averages have shown impressive strength to start the year. But the S&P 500 is up a little less than 4.5%, compared to year-to-date gains of nearly 15% in the SPDR S&P Biotech ETF (NYSE:XBI).

This outperformance is telling. Not only have biotech stocks remained vulnerable to political attack related to the drug pricing scandals that made headlines last year - they've also had to dig out of a nasty bear market.

All the controversy from the presidential campaign (along with some ill-timed Trump tweets) added up to a rough year for the health care sector. Even after bouncing off its winter lows, the group underperformed every other major sector on the market in 2016. Just a few weeks ago, we noted that the Health Care Select Sector SPDR (NYSE:XLV) had just registered its first annual loss since 2008.

But the group has exploded out of the gate in 2017. It was the strongest sector on the market during the first trading week of the year. And even as Trump tried to talk these stocks down, they're successfully fighting out of their collective funk.

The health care carnage appears to be coming to an end. Our favorite pharma stocks have finished crashing every time a price-gouging soundbite plays on the evening news. Of course, there are no guarantees that politics won't come back into play in the world of pharma and biotech. But price action is telling us that the worst of the biotech bashing might finally be over.

Now it's rally time.

>>>>> Scroll down to view and make comments <<<<<<

Click here for Historical Investing Post Listing










Make a Comment

Econintersect wants your comments, data and opinion on the articles posted. You can also comment using Facebook directly using he comment block below.




Econintersect Investing


search_box

Print this page or create a PDF file of this page
Print Friendly and PDF


The growing use of ad blocking software is creating a shortfall in covering our fixed expenses. Please consider a donation to Econintersect to allow continuing output of quality and balanced financial and economic news and analysis.


Take a look at what is going on inside of Econintersect.com
Main Home
Analysis Blog
Was Marx Right?
Angst in America, Part 5: The Crisis We Can’t Muddle Through
News Blog
Apr 25, 2017 08:01 GMT What Trump's Next 100 Days Will Look Like
How Did Small Businesses Do In 2016?
Costs Of Building A 355-Ship US Navy
The Roots Of Rising Treasury Yields
How Will College Grads Do In 2017 In Their Job Search
Recall This Bond Trader Chart? Here's What Happened
Infographic Of The Day: The Sad State Of America's Infrastructure In One Infographic
Early Headlines: High Worker Taxes, US Has Temp Funding, Net Neutrality Going?, Kurds Supported Erdogan, US To Crack Down On Iran, Russia C. Bank Easing, India Heat, H1B Scam, And More
Wiping Out Jobs Growth With Robotics
This Fantastic Idea For A Circular Runway Is Sadly Going Nowhere
Research Check: Are Aussie Women Ageing Up To 20 Years Faster Than US Women?
UFO Sightings Are At Record Heights
What We Read Today 28 April 2017
Investing Blog
The Last Time
Investing.com Weekly Wrap-Up 28 April 2017
Opinion Blog
New 'Gaullism' Rises In France
Blockchain: A Technology Whose Time Has Come
Precious Metals Blog
A New Age For Gold
Live Markets
28Apr2017 Market Close: Wall Street Closed Mostly Down On News The U.S. Economy Grew At Its Weakest Pace In Three Years, WTI Crude Settles In The Low 49 Handle
Amazon Books & More






.... and keep up with economic news using our dynamic economic newspapers with the largest international coverage on the internet
Asia / Pacific
Europe
Middle East / Africa
Americas
USA Government































 navigate econintersect.com

Blogs

Analysis Blog
News Blog
Investing Blog
Opinion Blog
Precious Metals Blog
Markets Blog
Video of the Day
Weather

Newspapers

Asia / Pacific
Europe
Middle East / Africa
Americas
USA Government
     

RSS Feeds / Social Media

Combined Econintersect Feed
Google+
Facebook
Twitter
Digg

Free Newsletter

Marketplace - Books & More

Economic Forecast

Content Contribution

Contact

About

  Top Economics Site

Investing.com Contributor TalkMarkets Contributor Finance Blogs Free PageRank Checker Active Search Results Google+

This Web Page by Steven Hansen ---- Copyright 2010 - 2017 Econintersect LLC - all rights reserved